The Administration of Probiotics against Hypercholesterolemia: A Systematic Review

Featured Application The current review helps find a better probiotic strain or probiotic mixture to develop probiotic-based adjuvant therapy to control hypercholesterolemia. Hypercholesterolemia is a key factor in the progression of atherosclerosis and cardiovascular disease (CVD). CVD is a significant public health concern with a high death rate. Some of the main factors linked to CVD include genetics and lifestyle. Dyslipidemia has been one of the factors related to the onset of several CVD-related diseases. Several clinicopathological studies have shown a correlation between high cholesterol levels, particularly low-density lipoprotein cholesterol (LDL-c), and CVD development. Probiotics have received a lot of attention for various beneficial effects, especially their ability to reduce blood cholesterol in humans. Probiotics were shown in several investigations to affect hypercholesterolemia by influencing cholesterol biosynthesis. The current review focuses on the human dietary interventions with probiotics and their effects on CVD risk factors and hypercholesterolemia. The outcomes are debatable and consider various parameters such as probiotic strain, dosing frequency, therapeutic response, dietary changes, and so forth. As a result, probiotics have the propensity to become dietary supplements in moderate/severe hypercholesterolemic patients, which significantly reduces the CVD risk.

Automated summary

This review explores the potential benefits of probiotics in reducing blood cholesterol levels and decreasing the risk of cardiovascular disease, particularly in high cholesterol patients. While probiotics show promise in lowering cholesterol, their effectiveness varies and depends on factors such as probiotic strain, dosing frequency, and dietary changes. Overall, probiotics have the potential to become dietary supplements for moderate/severe hypercholesterolemic patients, significantly reducing their risk of CVD.